Please evaluate response to neoadjuvant chemotherapy for breast cancer. There is heterogeneous amount of fibroglandular tissue in both breasts.Mild parenchymal enhancement is noted bilaterally.Interval decrease in the size and enhancement characteristics of the previously mentioned 3 enhancing masses in the central lateral right breast. The largest mass is seen as a curvilinear area of enhancement along the lateral aspect, and measures 2.9 x 0.8 x 1.2 cm, previously measured 3.8 x 4.1 x 3.4 cm. The postero- lateral mass demonstrates thick rim enhancement with central area of necrosis, and now measures 1.8 x 1 x 1.6 cm, previously measured 2.2 x 2.6 x 3.0 cm. The third anteromedial mass demonstrates thin rim enhancement and now measures 0.6 x 0.8 x 0.8 cm, previously measured 1.0 x 0.9 x 1.0 cm. The most anterior mass resides approximately 1 cm posterior to the nipple. Total area of enhancement in the right breast measures 1.3 x 5.3 x 1.4 cm, previously measured 3.8 x 6.9 x 4.5 cm and extends to the lateral cutaneous surface, mid depth, and to the lateral margin of the nipple. The retraction and the lateral deviation of the nipple has improved. Enhancement of the lateral aspect of the skin where the largest mass is in close proximity still persists.Interval decrease in size of right axillary lymph nodes. The largest lymph node with susceptibility artifact from a biopsy clip now measures 2.1 cm, previously measured 2.6 cm. The previously mentioned retropectoral lymph node now measures 1.6 cm, previously measured 1.9 cm. No abnormal enhancement is seen in the left breast. Multiple normal appearing lymph nodes are present in the left axilla.Chemotherapy port projected over the left medial chest wall.
Interval decrease in size of 3 masses in the right central breast and right axillary lymph nodes.No MRI evidence for malignancy in the left breast.BIRADS: 6 - Known cancer.RECOMMENDATION: T - Take Appropriate Action - No Letter.